.png)
.png)
HealthStream Announces Third Quarter 2018 Results
-
Revenues of
$59.9 million in the third quarter of 2018, up 9% from$54.7 million in the third quarter of 2017 with$634,000 positive impact in the third quarter of 2018 from the application of ASC 606 -
Operating income of
$4.7 million in the third quarter of 2018, up 71% from$2.7 million in the third quarter of 2017 with$1.1 million positive impact in the third quarter of 2018 from the application of ASC 606 -
Income from continuing operations of
$3.0 million in the third quarter of 2018, up 75% from$1.7 million in the third quarter of 2017 with$819,000 positive impact in the third quarter of 2018 from the application of ASC 606 -
Earnings per share (EPS) from continuing operations of
$0.09 per share (diluted) in the third quarter of 2018, compared to EPS from continuing operations of$0.06 per share (diluted) in the third quarter of 2017 -
Adjusted EBITDA1 from continuing operations of
$11.1 million in the third quarter of 2018, up 22% from$9.1 million in the third quarter of 2017 with$1.1 million positive impact in the third quarter of 2018 from the application of ASC 606 -
CFO
Gerard M. Hayden, Jr. tendered his resignation and will step down from his position inMarch 2019 ;Scott Roberts , Vice President of Accounting & Finance, will become Interim CFO following Hayden’s departure
Financial Results:
Third Quarter 2018 Compared to Third
Quarter 2017
On
Revenues for the third quarter of 2018 increased by
| 1 Adjusted EBITDA from continuing operations is a non-GAAP financial measure. A reconciliation of adjusted EBITDA to income from continuing operations and disclosure regarding why we believe adjusted EBITDA from continuing operations provides useful information to investors is included later in this release. |
Revenues from our HealthStream Workforce Solutions segment were
approximately
Revenues from our HealthStream Provider Solutions segment were
approximately
Generally accepted accounting principles (GAAP) require companies to
write down beginning balances of acquired deferred revenue balances as
part of “fair value” accounting as defined by GAAP. During the third
quarter of 2018,
Operating income was
Income from continuing operations was
Net income (from continuing and discontinued operations) was
Adjusted EBITDA from continuing operations increased to
Adjusted EBITDA (from continuing and discontinued operations) was
At
At
Year-to-Date 2018 Compared to Year-to-Date 2017
For the
first nine months of 2018, revenues were
Financial Impact of Adopting ASC 606
The chart on page
eleven under the heading of “Impact of Adoption of ASC 606” sets forth
what the revenues, operating income, net income from continuing
operations, adjusted EBITDA from continuing operations, and non-GAAP
operating income would have been for the third quarter of 2018 and first
nine months of 2018 if the prior revenue recognition standard was
applied (ASC 605).
2018 Events
On
Management Team Announcements
HealthStream’s Chief Financial
Officer,
To ensure a smooth transition following Mr. Hayden’s departure as CFO,
Financial Outlook for 2018
The Company adopted the new
revenue recognition standard (ASC 606) utilizing the modified
retrospective approach effective
The historical financial results of the PX business for periods prior to
the closing of this transaction are reflected in the Company’s
consolidated financial statements as discontinued operations.
Accordingly, this financial outlook for 2018 is for continuing
operations only and does not include (a) the gain on the sale of our PX
business, which we completed on
Consistent with our most recent earnings release issued on
For 2018, we continue to anticipate that consolidated revenues will increase six to eight percent as compared to 2017. We continue to anticipate that revenue growth in our Workforce Solutions segment will be in the four to six percent range and our Provider Solutions segment to grow 10 to 20 percent when compared to 2017.
We anticipate operating income for 2018 to increase between 45 and 60 percent as compared to 2017.
We anticipate that capital expenditures will be approximately
This guidance does not include the impact of any acquisitions or strategic investments that we may complete during 2018.
“As our CFO for the last decade and as a board member for two years
prior to that,
A conference call with
Use of Non-GAAP Financial Measures
This press release
contains certain non-GAAP financial measures, including non-GAAP net
income, non-GAAP operating income, adjusted EBITDA from continuing
operations, and adjusted EBITDA, which are used by management in
analyzing the Company’s financial results and ongoing operational
performance.
In order to better assess the Company’s financial results, management
believes that net income before interest, income taxes, share-based
compensation, depreciation and amortization, and changes in fair value
of cost method investments (“adjusted EBITDA”) is a useful measure for
evaluating the operating performance of the Company because adjusted
EBITDA reflects net income adjusted for certain non-cash and
non-operating items. Effective
In recent years, the Company has acquired businesses whose net tangible assets include deferred revenue. In accordance with GAAP reporting requirements, following the completion of any such acquisition, the Company may record a write-down of deferred revenue to fair value as defined by GAAP. If the Company is required to record a write-down of deferred revenue, it may result in lower recognized revenue, operating income, and net income in subsequent periods.
In connection therewith, this release presents below non-GAAP operating income and non-GAAP net income, which in each case reflects the corresponding GAAP figures adjusted to exclude the impact of the deferred revenue write-down associated with fair value accounting for acquired businesses as referenced above. Management believes that the presentation of these non-GAAP financial measures assists investors in understanding the Company’s performance between periods, excluding the impact of this deferred revenue write-down, and provides a useful measure of the ongoing performance of the Company. Both on a quarterly and year-to-date basis, the revenue for any acquired business is deferred and typically recognized over a one-to-two year period following the completion of an acquisition, so our GAAP revenues for this one-to-two year period will not reflect the full amount of revenues that would have been reported if the acquired deferred revenue had not been written down to fair value.
These non-GAAP financial measures should not be considered a substitute for, or superior to, measures of financial performance, which are prepared in accordance with GAAP, and may be different from non-GAAP financial measures used by other companies. Investors are encouraged to review the reconciliations of our GAAP to non-GAAP financial measures, which are set forth below in this release.
About
|
HEALTHSTREAM, INC. Condensed Consolidated Statements of Income (In thousands, except per share data) |
||||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||||
|
September 30, |
September 30, |
September 30, |
September 30, |
|||||||||||||||
| Revenues, net | $ | 59,925 | $ | 54,743 | $ | 171,791 | $ | 159,630 | ||||||||||
| Operating costs and expenses: | ||||||||||||||||||
| Cost of revenues (excluding depreciation and amortization) | 25,102 | 22,523 | 70,586 | 64,898 | ||||||||||||||
| Product development | 6,600 | 6,002 | 19,149 | 17,929 | ||||||||||||||
| Sales and marketing | 8,559 | 9,145 | 26,536 | 27,764 | ||||||||||||||
| Other general and administrative expenses | 8,997 | 8,371 | 24,769 | 23,269 | ||||||||||||||
| Depreciation and amortization | 6,006 | 5,971 | 18,097 | 17,874 | ||||||||||||||
| Total operating costs and expenses | 55,264 | 52,012 | 159,137 | 151,734 | ||||||||||||||
| Operating income | 4,661 | 2,731 | 12,654 | 7,896 | ||||||||||||||
| Other (loss) income, net | (548 | ) | 186 | 241 | 481 | |||||||||||||
| Income from continuing operations before income tax provision | 4,113 | 2,917 | 12,895 | 8,377 | ||||||||||||||
| Income tax provision | 1,077 | 1,182 | 2,575 | 2,709 | ||||||||||||||
| Income from continuing operations | 3,036 | 1,735 | 10,320 | 5,668 | ||||||||||||||
| Discontinued operations | ||||||||||||||||||
| Income (loss) from discontinued operations before income tax provision | — | 1,238 | (64 | ) | 762 | |||||||||||||
| Gain on sale of discontinued operations | — | — | 29,490 | — | ||||||||||||||
| Income tax provision | — | 469 | 10,319 | 374 | ||||||||||||||
| Income from discontinued operations | — | 769 | 19,107 | 388 | ||||||||||||||
| Net Income | $ | 3,036 | $ | 2,504 | $ | 29,427 | $ | 6,056 | ||||||||||
| Earnings per share – basic: | ||||||||||||||||||
| Continuing operations | $ | 0.09 | $ | 0.06 | $ | 0.32 | $ | 0.18 | ||||||||||
| Discontinued operations | — | 0.02 | 0.59 | 0.01 | ||||||||||||||
| Earnings per share - basic | $ | 0.09 | $ | 0.08 | $ | 0.91 | $ | 0.19 | ||||||||||
| Earnings per share - diluted: | ||||||||||||||||||
| Continuing operations | $ | 0.09 | $ | 0.06 | $ | 0.32 | $ | 0.18 | ||||||||||
| Discontinued operations | — | 0.02 | 0.59 | 0.01 | ||||||||||||||
| Earnings per share - diluted | $ | 0.09 | $ | 0.08 | $ | 0.91 | $ | 0.19 | ||||||||||
| Weighted average shares of common stock outstanding: | ||||||||||||||||||
| Basic | 32,322 | 31,893 | 32,244 | 31,848 | ||||||||||||||
| Diluted | 32,415 | 32,217 | 32,308 | 32,183 | ||||||||||||||
| Dividends declared per share | $ | — | $ | — | $ | 1.00 | $ | — | ||||||||||
|
HEALTHSTREAM, INC. Condensed Consolidated Balance Sheets (In thousands) |
||||||||||
| September 30, | December 31, | |||||||||
| 2018 |
2017(1) |
|||||||||
| ASSETS | ||||||||||
| Current assets: | ||||||||||
| Cash and cash equivalents | $ | 130,283 | $ | 84,768 | ||||||
| Marketable securities | 44,025 | 46,350 | ||||||||
| Accounts and unbilled receivables, net | 31,432 | 38,018 | ||||||||
| Prepaid and other current assets | 24,919 | 24,467 | ||||||||
| Current assets of discontinued operations | — | 6,125 | ||||||||
| Total current assets | 230,659 | 199,728 | ||||||||
| Capitalized software development, net | 16,770 | 16,014 | ||||||||
| Property and equipment, net | 8,683 | 8,092 | ||||||||
| Goodwill and intangible assets, net | 147,794 | 154,641 | ||||||||
| Deferred tax assets | — | 45 | ||||||||
| Deferred commissions | 13,474 | — | ||||||||
| Other assets | 4,120 | 4,526 | ||||||||
| Long-term assets of discontinued operations | — | 28,073 | ||||||||
| Total assets | $ | 421,500 | $ | 411,119 | ||||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||||
| Current liabilities: | ||||||||||
| Accounts payable, accrued and other liabilities | $ | 35,358 | $ | 29,356 | ||||||
| Deferred revenue | 62,151 | 64,938 | ||||||||
| Current liabilities of discontinued operations | — | 6,772 | ||||||||
| Total current liabilities | 97,509 | 101,066 | ||||||||
| Deferred tax liabilities | 5,082 | — | ||||||||
| Deferred revenue, non-current | 2,333 | 6,287 | ||||||||
| Other long-term liabilities | 882 | 1,048 | ||||||||
| Long-term liabilities of discontinued operations | — | 2,548 | ||||||||
| Total liabilities | 105,806 | 110,949 | ||||||||
| Shareholders’ equity: | ||||||||||
| Common stock | 286,128 | 282,666 | ||||||||
| Accumulated other comprehensive loss | (17 | ) | (38 | ) | ||||||
| Retained earnings | 29,583 | 17,542 | ||||||||
|
Total shareholders’ equity |
315,694 | 300,170 | ||||||||
|
Total liabilities and shareholders’ equity |
$ | 421,500 | $ | 411,119 | ||||||
|
(1) |
Derived from audited financial statements contained in the Company’s filing on Form 10-K for the year ended December 31, 2017, adjusted for the divestiture of the PX business segment. | |
|
HEALTHSTREAM, INC. Condensed Consolidated Statements of Cash Flows (In thousands) |
||||||||||
| Nine Months Ended | ||||||||||
| September 30, | September 30, | |||||||||
| 2018 | 2017 | |||||||||
| Operating activities: | ||||||||||
| Net income | $ | 29,427 | $ | 6,056 | ||||||
| Income from discontinued operations | (19,107 | ) | (388 | ) | ||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||
| Depreciation and amortization | 18,097 | 17,874 | ||||||||
| Share-based compensation | 1,306 | 1,241 | ||||||||
| Deferred income taxes | 661 | 710 | ||||||||
| Provision for doubtful accounts | 690 | 820 | ||||||||
| (Gain) loss on equity method investments | (25 | ) | 5 | |||||||
| Change in fair value of cost method investments | 1,271 | — | ||||||||
| Other | (22 | ) | 351 | |||||||
| Changes in assets and liabilities: | ||||||||||
| Accounts and unbilled receivables | 5,865 | 4,422 | ||||||||
| Prepaid and other assets | (1,441 | ) | 885 | |||||||
| Accounts payable, accrued and other liabilities | (7,576 | ) | 1,841 | |||||||
| Deferred revenue | 658 | (1,464 | ) | |||||||
| Net cash provided by continuing operating activities | 29,804 | 32,353 | ||||||||
| Net cash (used in) provided by discontinued operating activities | (1,003 | ) | 3,310 | |||||||
| Net cash provided by operating activities | 28,801 | 35,663 | ||||||||
| Investing activities: | ||||||||||
| Proceeds from sale of discontinued operations | 57,827 | — | ||||||||
| Changes in marketable securities | 2,367 | (9,724 | ) | |||||||
| Payments to acquire cost method investments | (833 | ) | (500 | ) | ||||||
| Purchases of property and equipment | (4,342 | ) | (4,828 | ) | ||||||
| Payments associated with capitalized software development | (8,042 | ) | (7,480 | ) | ||||||
| Net cash provided by (used in) continuing investing activities | 46,977 | (22,532 | ) | |||||||
| Net cash used in discontinued investing activities | (115 | ) | (2,217 | ) | ||||||
| Net cash provided by (used in) investing activities | 46,862 | (24,749 | ) | |||||||
| Financing activities: | ||||||||||
| Proceeds from exercise of stock options | 2,582 | 322 | ||||||||
| Taxes paid related to net settlement of equity awards | (335 | ) | (410 | ) | ||||||
| Payment of earn-outs related to prior acquisitions | (38 | ) | — | |||||||
| Payment of cash dividends | (32,357 | ) | — | |||||||
| Net cash used in continuing financing activities | (30,148 | ) | (88 | ) | ||||||
| Net cash used in discontinued financing activities | — | — | ||||||||
| Net cash used in financing activities | (30,148 | ) | (88 | ) | ||||||
| Net increase in cash and cash equivalents | 45,515 | 10,826 | ||||||||
| Cash and cash equivalents at beginning of period | 84,768 | 49,634 | ||||||||
| Cash and cash equivalents at end of period | $ | 130,283 | $ | 60,460 | ||||||
|
Reconciliation of GAAP to Non-GAAP Financial Measures(1) (In thousands) |
||||||||||||||||||||
|
Three Months Ended |
Nine Months Ended |
|||||||||||||||||||
| 2018 | 2017 | 2018 | 2017 | |||||||||||||||||
| GAAP income from continuing operations | $ | 3,036 | $ | 1,735 | $ | 10,320 | $ | 5,668 | ||||||||||||
| Interest income | (736 | ) | (221 | ) | (1,586 | ) | (583 | ) | ||||||||||||
| Interest expense | 32 | 35 | 98 | 97 | ||||||||||||||||
| Income tax provision | 1,077 | 1,182 | 2,575 | 2,709 | ||||||||||||||||
| Stock based compensation expense | 459 | 401 | 1,306 | 1,241 | ||||||||||||||||
| Depreciation and amortization | 6,006 | 5,971 | 18,097 | 17,874 | ||||||||||||||||
| Change in fair value of cost method investments | 1,271 | — | 1,271 | — | ||||||||||||||||
| Adjusted EBITDA from continuing operations | $ | 11,145 | $ | 9,103 | $ | 32,081 | $ | 27,006 | ||||||||||||
| GAAP net income | $ | 3,036 | $ | 2,504 | $ | 29,427 | $ | 6,056 | ||||||||||||
| Interest income | (736 | ) | (221 | ) | (1,586 | ) | (583 | ) | ||||||||||||
| Interest expense | 32 | 35 | 98 | 97 | ||||||||||||||||
| Income tax provision | 1,077 | 1,651 | 12,894 | 3,083 | ||||||||||||||||
| Stock based compensation expense | 459 | 440 | 1,215 | 1,358 | ||||||||||||||||
| Depreciation and amortization | 6,006 | 6,570 | 18,279 | 19,488 | ||||||||||||||||
| Change in fair value of cost method investments | 1,271 | — | 1,271 | — | ||||||||||||||||
| Adjusted EBITDA | $ | 11,145 | $ | 10,979 | $ | 61,598 | $ | 29,499 | ||||||||||||
| GAAP operating income | $ | 4,661 | $ | 2,731 | $ | 12,654 | $ | 7,896 | ||||||||||||
| Adjustment for deferred revenue write-down | 703 | 146 | 779 | 1,539 | ||||||||||||||||
| Non-GAAP operating income | $ | 5,364 | $ | 2,877 | $ | 13,433 | $ | 9,435 | ||||||||||||
| GAAP net income | $ | 3,036 | $ | 2,504 | $ | 29,427 | $ | 6,056 | ||||||||||||
| Adjustment for deferred revenue write-down, net of tax | 519 | 87 | 583 | 1,077 | ||||||||||||||||
| Non-GAAP net income | $ | 3,555 | $ | 2,591 | $ | 30,010 | $ | 7,133 | ||||||||||||
|
(1) |
This press release contains certain non-GAAP financial measures, including non-GAAP net income, non-GAAP operating income, adjusted EBITDA, and adjusted EBITDA from continuing operations, which are used by management in analyzing its financial results and ongoing operational performance. | |
|
Impact of Adoption of ASC 606 |
||||||||||||||||
|
Three Months Ended September 30, |
||||||||||||||||
| 2018 | 2017 | |||||||||||||||
|
ASC 606 As reported |
Adjustments from ASC 606 to ASC 605 |
ASC 605 As adjusted |
ASC 605 | |||||||||||||
| Revenue | $ | 59,925 | $ | 634 | $ | 59,291 | $ | 54,743 | ||||||||
| Operating income | 4,661 | 1,109 | 3,552 | 2,731 | ||||||||||||
| Income from continuing operations | 3,036 | 819 | 2,217 | 1,735 | ||||||||||||
| Adjusted EBITDA from continuing operations | 11,145 | 1,109 | 10,036 | 9,103 | ||||||||||||
| Non-GAAP operating income | 5,364 | 1,109 | 4,255 | 2,877 | ||||||||||||
|
Nine Months Ended |
||||||||||||||||
| 2018 | 2017 | |||||||||||||||
|
ASC 606 |
Adjustments |
ASC 605 |
ASC 605 | |||||||||||||
| Revenue | $ | 171,791 | $ | 738 | $ | 171,053 | $ | 159,630 | ||||||||
| Operating income | 12,654 | 2,506 | 10,148 | 7,896 | ||||||||||||
| Income from continuing operations | 10,320 | 2,006 | 8,314 | 5,668 | ||||||||||||
| Adjusted EBITDA from continuing operations | 32,081 | 2,506 | 29,575 | 27,006 | ||||||||||||
| Non-GAAP operating income | 13,433 | 2,506 | 10,927 | 9,435 | ||||||||||||
This press release includes certain forward-looking statements
(statements other than solely with respect to historical fact),
including statements regarding expectations for the financial
performance for 2018, that involve risks and uncertainties regarding
View source version on businesswire.com: https://www.businesswire.com/news/home/20181022005794/en/
Source:
HealthStream, Inc.
Gerard M. Hayden, Jr., 615-301-3163
Chief
Financial Officer
ir@healthstream.com
or
Media:
Mollie
Condra, Ph.D., 615-301-3237
Vice President, Investor Relations &
Communications
mollie.condra@healthstream.com